Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_assertion type Assertion NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_head.
- NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_assertion description "[The vast majority of colon (80%) and breast (60%) tumors and sarcomas (73%) express CRD-BP whereas in other tumor types, for example prostate carcinomas, its expression is rare.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_provenance.
- NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_assertion evidence source_evidence_literature NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_provenance.
- NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_assertion SIO_000772 12894594 NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_provenance.
- NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_assertion wasDerivedFrom befree-20140225 NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_provenance.
- NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_assertion wasGeneratedBy ECO_0000203 NP221191.RAUktn_Hba4HmcPiJcQWXIge8C3MXhS6O469_NXOTuXSg130_provenance.